^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CCND1 (Cyclin D1)

    i
    Other names: CCND1, BCL1, D11S287E, PRAD1, U21B31, Cyclin D1
    19h
    LncRNA IRAIN inhibits mantle cell lymphoma progression by inducing cell cycle arrest and apoptosis: an in vitro study. (PubMed, Sci Rep)
    Collectively, these findings suggest that IRAIN may participate in the regulation of proliferation, apoptosis, and cell cycle progression in MCL cells, potentially through modulation of LSD1. These results provide preliminary experimental evidence for further understanding the potential biological function of IRAIN in MCL.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • KDM1A (Lysine Demethylase 1A) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    1d
    Identification and validation of prognostic genes related to centrosome amplification in multiple myeloma. (PubMed, PeerJ)
    RT-qPCR validation confirmed a significant up- regulation of these six genes in MM. Six prognostic genes associated with CA in MM were identified, and a predictive risk model was developed, offering valuable insights for clinical prognosis and immunotherapy in MM.
    Journal • IO biomarker
    |
    CCND1 (Cyclin D1) • ARL2 (ADP Ribosylation Factor Like GTPase 2) • RUVBL1 (RuvB Like AAA ATPase 1)
    1d
    Selective Anticancer Effects of Portulaca grandiflora via Apoptosis and NF-κB Pathway Modulation in MDA-MB-231 Cells. (PubMed, Appl Biochem Biotechnol)
    Because pathway-causality was not tested using NF-κB rescue or pharmacological inhibition controls, the mechanistic conclusions are presented as supportive associations rather than definitive proof. Future studies should focus on bioassay-guided compound purification, synergistic combination assessment, and in vivo validation for translational advancement.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL2L1 (BCL2-like 1) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • XIAP (X-Linked Inhibitor Of Apoptosis) • CASP7 (Caspase 7) • NFKBIA (NFKB Inhibitor Alpha 2) • ANXA5 (Annexin A5)
    2d
    A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) (clinicaltrials.gov)
    P1/2, N=106, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Inokai (orelabrutinib)
    2d
    BIRC5 drives cell-cycle dysregulation and represents a novel molecular target in retinoblastoma. (PubMed, Front Oncol)
    Conversely, BIRC5 knockdown induced G1 cell cycle arrest and increased apoptotic activity, accompanied by activation of checkpoint pathways. This study defines BIRC5 as a cell-state-specific regulator of malignant proliferation in retinoblastoma and provides a mechanistic rationale for targeting survivin in highly proliferative tumor subpopulations.
    Journal
    |
    RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CHEK2 (Checkpoint kinase 2) • BIRC5 (Baculoviral IAP repeat containing 5) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    2d
    Revealing key biomarkers and molecular mechanisms associated with di(2-ethylhexyl) phthalate in skin cancer. (PubMed, Front Mol Biosci)
    Collectively, this study systematically elucidates the toxicological mechanism by which DEHP promotes skin cancer development through subtype-specific pathways regulated by 11 key targets, clarifying its direct binding patterns with core targets and downstream pathway disruption characteristics. This not only fills a research gap in the molecular mechanisms of DEHP-induced skin carcinogenesis but also provides novel biomarkers for environmental exposure prevention and targeted interventions against skin cancer.
    Journal • IO biomarker
    |
    ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1) • IL6 (Interleukin 6) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3)
    2d
    Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset. (PubMed, Int J Urol)
    Using a large-scale Japanese genomic panel dataset, we characterized the molecular alterations associated with S/DD. S/DD frequently exhibits low Nectin-4 expression and basal-like molecular features, which may have implications for treatment selection and inform future therapeutic strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • KDM6A (Lysine Demethylase 6A) • FGF4 (Fibroblast growth factor 4) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • GATA3 (GATA binding protein 3) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression • TP53 mutation • EGFR expression • ARID1A mutation • FGFR3 mutation • RB1 mutation
    2d
    Comparative Genomic Profiling and Prognostic Impact in Recurrent and/or Metastatic Hypopharyngeal and Esophageal Squamous Cell Carcinoma. (PubMed, Laryngoscope Investig Otolaryngol)
    Moreover, alterations in CCND1 and FGF family genes were associated with poor prognosis, highlighting their potential roles as prognostic biomarkers and therapeutic targets in ESCC. III.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • FGF3 (Fibroblast growth factor 3) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • FGF4 (Fibroblast growth factor 4)
    |
    NFE2L2 mutation
    4d
    The role of p53-mediated signaling pathways in nicotine-induced cancer: a systematic review. (PubMed, Food Chem Toxicol)
    Nicotine's impact on p53 is highly context-dependent: it inactivates wild-type p53 while enhancing gain-of-function of mutant p53, particularly p53-RS. This review expands the theoretical framework of nicotine-induced carcinogenesis, highlights concerns regarding alternative nicotine delivery systems and crosstalk between oxidative stress and p53 regulation, and provides a scientific basis for early diagnosis, targeted therapy, and prevention of smoking-related cancers.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • CCND1 (Cyclin D1) • CDK6 (Cyclin-dependent kinase 6) • MMP9 (Matrix metallopeptidase 9) • SETDB1 (SET Domain Bifurcated Histone Lysine Methyltransferase 1)
    |
    TP53 mutation • TP53 wild-type
    5d
    Clinicopathological and molecular features of wild-type gastrointestinal stromal tumors identified by targeted NGS. (PubMed, Histol Histopathol)
    WT GISTs exhibit considerable molecular heterogeneity with novel or rare mutations of uncertain significance. Targeted NGS enables the detection of clinically relevant alterations that may guide future diagnostic and therapeutic strategies. Our findings emphasize the importance of targeted molecular profiling and raise the potential for personalized treatment in this challenging subset of GISTs.
    Journal • Next-generation sequencing
    |
    FLT3 (Fms-related tyrosine kinase 3) • RB1 (RB Transcriptional Corepressor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
    |
    PDGFRA mutation
    5d
    PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma. (PubMed, J Neurooncol)
    These findings identify a PKA/PRMT5/hnRNP A1 signaling axis that promotes IRES-dependent translation and contributes to mTOR inhibitor resistance in GBM. Dual inhibition of PKA and mTOR may represent a promising therapeutic strategy.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • PRMT5 (Protein Arginine Methyltransferase 5)
    6d
    Butyrate blocks cell cycle progression in colorectal cancer organoids partially through HDAC2 inhibition. (PubMed, Front Immunol)
    Butyrate modulates cell cycle via targeting HDAC2, constituting a novel therapeutic pathway for CRC. This study provides new evidence for gut microbial metabolites as a potential means for the prevention and treatment of colorectal cancer.
    Journal
    |
    CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • HDAC2 (Histone deacetylase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)